Karyopharm Therapeutics Inc. Debt Securities, Available-for-sale, Amortized Cost
Karyopharm Therapeutics Inc. (KPTI) had Debt Securities, Available-for-sale, Amortized Cost of $46.17 million as of 2024-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-02-13
- 2024-12-31: Debt Securities, Available-for-sale, Amortized Cost $46.17M.
- 2024-09-30: Debt Securities, Available-for-sale, Amortized Cost $60.52M.
- 2024-06-30: Debt Securities, Available-for-sale, Amortized Cost $67.47M.
- 2024-03-31: Debt Securities, Available-for-sale, Amortized Cost $118.06M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2024-12-31 | $46.17M 10-K · filed 2026-02-13 |
| 2024-09-30 | $60.52M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $67.47M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $118.06M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $139.28M 10-K · filed 2025-02-19 |
| 2023-09-30 | $165.10M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $156.48M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $176.64M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $143.12M 10-K · filed 2024-02-29 |
| 2022-09-30 | $77.36M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $88.78M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $52.07M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $38.16M 10-K · filed 2023-02-17 |
| 2020-12-31 | $187.26M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |